Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Amneal acquires Kashiv BioSciences for biosimilars

PUBLIC · AMRXAug 10, 2026•about 2 hours ago

Acquiring Company

Amneal Pharmaceuticals

Acquired Company

Kashiv BioSciences

BridgewaterManufacturingBiotechnologyHealth Care

Description

Amneal Pharmaceuticals has completed its acquisition of Kashiv BioSciences, creating a global leader in biosimilars. This strategic move establishes a fully integrated platform for research, development, and commercialization. The acquisition enhances Amneal's growth profile and positions the company to capitalize on upcoming biologic loss of exclusivity. Integration activities are currently underway to combine the companies' strengths.

Company Information

Company

Amneal Pharmaceuticals

About

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of approximately 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit www.amneal.com.

Related People

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Amneal Pharmaceuticals's next move

Learn about Strategic plan

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Kashiv BioSciences?

Kashiv BioSciences was acquired by Amneal Pharmaceuticals. The deal was reported on August 10, 2026. Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated essential medicines company. Amneal Pharmaceuticals is publicly traded (AMRX).

When did Amneal Pharmaceuticals acquire Kashiv BioSciences?

Amneal Pharmaceuticals's acquisition of Kashiv BioSciences was reported on August 10, 2026. Amneal Pharmaceuticals has completed its acquisition of Kashiv BioSciences, creating a global leader in biosimilars. This strategic move establishes a fully integrated platform for research, development, and commercialization. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Kashiv BioSciences do?

Kashiv BioSciences, LLC is a company that focuses on developing and manufacturing high-quality, affordable biosimilars to improve patients’ lives worldwide. It is privately held, operating in Manufacturing, and is based in Bridgewater.